By continuing to use this site you consent to the use of cookies on your device. Find out more about our cookie policy and the types of cookies we use by clicking here

Amryt Pharma Gets Go-Ahead For Phase 3 Trial Of Skin Disorder Drug

LONDON (Alliance News) - Amryt Pharma PLC on Monday said it is on track to commence the phase 3 ...

Alliance News 6 March, 2017 | 11:05AM
Email Form

LONDON (Alliance News) - Amryt Pharma PLC on Monday said it is on track to commence the phase 3 trial of AP101 at the end of March after completing regulatory discussions with the US Food & Drug Administration and the European Medicines Agency.

AP101 is being trialled as a potential treatment for epidermolysis bullosa, which is a rare genetic skin disorder which leads to exceptionally fragile skin.

Approximately 30 clinical trial sites in 15 countries have been pre-qualified for the trial, where 164 patients will be treated for a 90-day period.

"We are delighted to have reached this critical milestone in the development of Amryt. Reaching agreement with the regulatory authorities for our phase 3 study in EB was a precursor to commencing our pivotal study, which we now expect will enrol its first patients in the coming weeks," Chief Executive Joe Wiley said in a statement.

"We believe that the adaptive approach to study sample size will help to ensure that we achieve a reliable assessment of the potential benefit of our new skin healing treatment in this orphan disease," Chief Medical Officer Mark Sumeray added.

Shares in Amryt were trading up 7.4% at 19.60 pence on Monday.

By Karolina Kaminska;; @KarolinaAllNews

Copyright 2017 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar
Amryt Pharma PLC 17.63 GBX -0.70 -
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.